Rare Disease and Orphan Drugs Journal
All Journals
Search
Log In
Editor-in-Chief:
Daniel Scherman
Indexing:
Dimensions
,
Lens
,
Submission to first decision:
72 days
Hot Keywords
rare disease
orphan drug
Home
About
About the Journal
Aims and Scope
Editorial Policies
Editorial Board
Junior Editorial Board
News
Partners
Advertise
Contact Us
Publish with us
For Authors
Author Instructions
Article Processing Charges
Editorial Process
Manuscript Templates
Submit a Manuscript
For Reviewers
Peer Review Guidelines
Articles
All Articles
Articles with Video Abstracts
Video Abstract Guidelines
Special Issues
All Special Issues
Ongoing Special Issues
Completed Special Issues
Closed Special Issue
Special Issue Ebooks
Special Issue Guidelines
Volumes
Pre-onlines
Features
Interviews
Webinars
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Rare Disease and Orphan Drugs Journal
Search
Submit
Editor-in-Chief:
Daniel Scherman
Submission to first decision:
72 days
Home
Articles
Special Issues
Volumes
Webinars
Videos
Menu
Home
Articles
Article
Image
fig2
From:
Next-generation sequencing-based newborn screening initiatives in Europe: an overview
Figure 2. Desired impact on stakeholders.
Back
Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
editorialoffice@rdodjournal.com
Navigation
Contact Us
Sitemap
Follow Us
Twitter
LinkedIn
Navigation
Contact Us
Sitemap
Committee on Publication Ethics
https://publicationethics.org/members/rare-disease-and-orphan-drugs-journal
Portico
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/
Committee on Publication Ethics
https://publicationethics.org/members/rare-disease-and-orphan-drugs-journal
Portico
All published articles are preserved here permanently:
https://www.portico.org/publishers/oae/